Post A Reply
Allstocks.com's Bulletin Board
.11 and Up!
CTIX -- Cellceutix Corporation
» Post A Reply
Post A Reply
HTML is enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by moogoo gaipan: [QB] Pharmaceutical Micro-Cap Company Demonstrates Significant Delay of Tumor Growth in Drug Resistant Breast Cancer By: **************.com News September 22, 2009 It is the scourge of our era, and that era’s women. More than 1.3 million women worldwide are diagnosed with breast cancer annually, and more than a third of these (465,000) will lose their battle with the deadly disease. About 41,000 of these deaths will be in the United States, according to the latest figures from the American Cancer Society. The cry for a treatment, a cure - to be more optimistic, a preventive measure – is growing louder day by day, for these numbers are tragically high. Fortunately, the cry is being heard in several quarters of the medical community, provoking cheers of delight from patients, their doctors, and small cap investors. On the last official, full day of summer came word from Cellceutix Corporation (OTCBB:CTIX), a Massachusetts-based researcher, that successful tests had been completed on animals involving the company’s pharmaceutical compound known as Kevetrin™. The tests were performed on a taxane-resistant, estrogen receptor-negative breast cancer human cell line, MDA-MB-435s, and compared favorably with other cancer fighters such as paclitaxel and cisplaten in delaying tumor growth. A news release, issued after the closing bell on September 21, reported that tumor volume was reduced by 72%, tumor growth by 52%, results that were far superior to the other two substances. There was also no significant weight loss in the mice used in the experiments. CTIX President, Dr. Krishna Menon, said the results were consistent with those of multi-drug resistant lung cancer cell lines the company came out with in July. Cellceutix, based in the town of Beverly, MA, owns the rights to seven drug compounds, including Kevetrin which it is developing as a treatment for certain cancers, and KM-133, which it is developing for the treatment of psoriasis. On its website, CTIX likens its approach to drug research to that of New England weather; if you don’t like it, wait a minute. By which the company means, if things look dull on the research front, folks are urged to remember that developments change day to day, and that they never know what to expect. The company’s exploits with Kevetrin provide a case in point. The product was initially applied to fighting head and neck cancers, a market CTIX considers underserviced, but has also since been applied to the battle against other cancers, as we have seen. The patent battle involving Kevetrin is one the higher-ups at the company consider well worth it, as, quote, “this complex and far-reaching patent is now filed with much broader claims than we imagined at the beginning of the patent process.” Simply put, Kevetrin has all the marking of a flagship product for Cellceutix. The news of the successful tests were greeted with plenty of investor interest; although the price dipped a dime to about 70 cents the day after the press release, volume was at its yearly high, showing that investors are seeing value in this pharmaceutical micro-cap. While the stock is still in bargain territory, it’s appreciably dearer than the 15-cent mark at which the company found itself last November, giving bargain sleuths a stronger sense of urgency. . [/QB][/QUOTE]
Instant UBB Code™
What is UBB Code™?
Disable Graemlins in this post.
*** Click here to review this topic. ***
Allstocks.com Message Board Home
© 1997 - 2018 Allstocks.com. All rights reserved.